source
- AstraZeneca hints restructuring may trim R&D budget and move trials to emerging marketsAstraZeneca's chief executive Pascal Soriot told journalists that the company's new restructuring program could lead to cost reductions in research and development and may see some clinical trials…
- Sanofi says no major restructuring despite upcoming Dupixent patent expirationSanofi's new chief executive, Belén Garijo, said after six months in charge that the company will not embark on a major overhaul of its business or research pipeline. The comment was made as the b…